LEO Pharma Announces Changes to Executive Leadership
null
Ballerup, 29 January 2025 – Today, LEO Pharma announces the appointment of a new Executive Vice President, North America. Robert Spurr will join the Global Leadership Team and serve as CEO and President, LEO Pharma Inc. United States. Robert succeeds Brian Hilberdink, who will be leaving LEO Pharma to pursue an external opportunity in a large pharmaceutical company.
Robert joined LEO Pharma in 2023 as Vice President of Market Access, Patient Services, Sales, and Health Economics and Outcomes Research (HEOR) and a member of the North America Leadership Team. Prior to LEO Pharma, he previously held numerous senior leadership positions at Novartis, Johnson and Johnson, and Repligen. Robert also served as President of Bausch Healthcare Companies Inc.
“I am thrilled to step into the role of EVP of Region North America and CEO & President of LEO Pharma Inc. US,” said Robert Spurr “As LEO Pharma undergoes significant transformation with a clear strategy for the future, I am eager to leverage my experience to drive our continued success. With a strong growth trajectory and a dedicated team, I am confident we can deliver great results.”
Robert Spurr will officially step into the EVP role on January 29, 2025. Brian Hilberdink’s last day at LEO Pharma will be on February 11, 2025.
“During my tenure at LEO Pharma, I have witnessed the incredible drive and passion across Region North America. I’m proud to have had the opportunity to lead and help propel the Region into a significant growth trajectory,” said Brian Hilberdink, former EVP of Region North America and CEO & President of LEO Pharma Inc. US. “It has not been an easy decision to leave LEO Pharma, and I have every confidence in the future success of the organization.”
“I would like to thank Brian for his key contribution in accelerating LEO Pharma’s growth trajectory in North America and for building a strong team,” said LEO Pharma CEO, Christophe Bourdon. “Robert’s track record and leadership qualities make him ideally suited to his new role. Over the last 18 months I have been truly impressed by his key contributions to the US affiliate. I would like to congratulate him on his appointment and welcome him as a member of LEO Pharma’s Global Leadership Team. His contributions will be instrumental in further strengthening our growth trajectory in North America.”
Kontakter
Jeppe Ilkjær
LEO Pharma, Global Communications
Tel: +45 30 50 20 14
Email: JEILK@leo-pharma.com
About LEO Pharma
LEO Pharma is a global company dedicated to advancing the standard of care through innovation for the benefit of people with skin conditions. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. LEO Pharma offers a broad portfolio of treatments, serving 100 million patients annually. Headquartered in Denmark, LEO Pharma has a global team of 4,000 people. In 2023, the company generated net sales of DKK 11.4 billion.
Følg pressemeddelelser fra LEO Pharma
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra LEO Pharma
LEO Pharma delivers 7% revenue growth at CER in H1 2025 and achieves key milestones enabling future growth18.8.2025 12:00:00 CEST | Pressemeddelelse
Ballerup, Denmark, 18 August, 2025 - In H1 2025, LEO Pharma delivered robust growth and significantly improved profitability, enabling an increase to the financial outlook for sales growth and adjusted EBITDA margin in 2025 towards the upper-end of previously communicated expectations. In July, the FDA approval of Anzupgo® and partnership with Boehringer Ingelheim for SPEVIGO®, marked major strategic milestones demonstrating LEO Pharma’s commitment to advancing innovation in dermatology. Highlights LEO Pharma’s revenue increased by 6% year-on-year to DKK 6,789 million, and by 7% at constant exchange rates (CER) entirely driven by organic growth. The revenue growth was led by North America (+28% at CER), with Europe (+1% at CER) and Rest of World (+4% at CER) also contributing to the overall growth. Revenue from the Dermatology portfolio grew by 8% (CER) year-on-year, driven by the Strategic brands Adtralza®/Adbry® and Anzupgo®, which combined had a revenue increase of 51% (CER). Sales
LEO Pharma Announces FDA Approval of ANZUPGO® (delgocitinib) Cream in the U.S.23.7.2025 22:30:00 CEST | Pressemeddelelse
ANZUPGO® (delgocitinib) cream now becomes the first and only FDA-approved treatment specifically approved for the treatment of adults living with moderate-to-severe chronic hand eczema (CHE) in the U.S.1 CHE affects approximately one in ten adults worldwide, yet previously, there has been no specific treatment FDA-approved for those living with the disease.2,3 The approval represents an important milestone for LEO Pharma’s expanding presence in the U.S. as it broadens its portfolio of dermatology treatments to address unmet needs.
Boehringer Ingelheim and LEO Pharma enter partnership to commercialize and further develop SPEVIGO® (spesolimab)14.7.2025 13:00:00 CEST | Pressemeddelelse
Partnership will accelerate and broaden access to treatment for more patients with generalized pustular psoriasis (GPP), a rare and devastating skin condition LEO Pharma’s six decades of dermatology expertise and Boehringer’s global track record in bringing SPEVIGO® to over 40 countries will be combined to ensure continuous patient support Boehringer Ingelheim and LEO Pharma will closely cooperate to ensure a smooth transition of all operations
LEO Pharma Announces Positive 16-Week Interim Results for ADHAND Trial for Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis on the Hands who are Candidates for Systemic Therapy9.7.2025 13:00:00 CEST | Pressemeddelelse
ADHAND is a phase 3b placebo-controlled clinical trial evaluating the efficacy and safety of tralokinumab in adult patients living with moderate-to-severe atopic dermatitis on the hands who are candidates for systemic therapy.1 The 16-week interim results of the ADHAND trial met the primary and all key secondary endpoints, showing statistically significant results compared to placebo. This analysis assessed outcomes up to Week 16, but the trial will continue through Week 32, with final results expected by the end of the year.
LEO Pharma Initiates Phase 2a DELTA NEXT Trial of Delgocitinib Cream in Adults with Mild to Severe Palmoplantar Pustulosis (PPP)3.6.2025 09:00:00 CEST | Pressemeddelelse
The phase 2a proof-of-concept trial will recruit up to 135 adult patients with mild to severe PPP to investigate the efficacy and safety of delgocitinib cream compared to cream vehicle. Delgocitinib cream has been shown to inhibit the activity of all four JAKs,(1,2) making it a potential therapeutic candidate for treating PPP.
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum